Brook R - Search Results

1

Impact of personal and ambient-level exposures to nitrogen dioxide and particulate matter on cardiovascular function.

Williams R, Brook R, Bard R, Conner T, Shin H, Burnett R. Williams R, et al. Among authors: brook r. Int J Environ Health Res. 2012;22(1):71-91. doi: 10.1080/09603123.2011.588437. Epub 2011 Jun 28. Int J Environ Health Res. 2012. PMID: 21711166 Free PMC article.

2

Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults.

Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Brook RD, et al. Am J Cardiol. 2001 Dec 1;88(11):1264-9. doi: 10.1016/s0002-9149(01)02088-4. Am J Cardiol. 2001. PMID: 11728354

3

Hypertension and triglyceride catabolism: implications for the hemodynamic model of the metabolic syndrome.

Brook RD, Glazewski L, Rajagopalan S, Bard RL. Brook RD, et al. J Am Coll Nutr. 2003 Aug;22(4):290-5. doi: 10.1080/07315724.2003.10719306. J Am Coll Nutr. 2003. PMID: 12897043

4

Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults.

Brook RD, Bard RL, Glazewski L, Kehrer C, Bodary PF, Eitzman DL, Rajagopalan S. Brook RD, et al. Am J Cardiol. 2004 Apr 15;93(8):1012-6. doi: 10.1016/j.amjcard.2004.01.009. Am J Cardiol. 2004. PMID: 15081445

5

Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention.

Bard RL, Kalsi H, Rubenfire M, Wakefield T, Fex B, Rajagopalan S, Brook RD. Bard RL, et al. Am J Cardiol. 2004 Apr 15;93(8):1030-2. doi: 10.1016/j.amjcard.2003.12.056. Am J Cardiol. 2004. PMID: 15081449

6

Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension.

Valentini M, Julius S, Palatini P, Brook RD, Bard RL, Bisognano JD, Kaciroti N. Valentini M, et al. J Hypertens. 2004 Oct;22(10):1999-2006. doi: 10.1097/00004872-200410000-00024. J Hypertens. 2004. PMID: 15361773 Clinical Trial.

7

Utility of C-reactive protein measurement in risk stratification during primary cardiovascular disease prevention.

Bard RL, Rubenfire M, Eagle K, Clarke NS, Brook RD. Bard RL, et al. Am J Cardiol. 2005 Jun 1;95(11):1378-9. doi: 10.1016/j.amjcard.2005.01.089. Am J Cardiol. 2005. PMID: 15904650

8

Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.

Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, Rajagopalan S, Pitt B. Bleske BE, et al. J Am Coll Cardiol. 2006 Jan 17;47(2):338-41. doi: 10.1016/j.jacc.2005.06.087. Epub 2005 Dec 20. J Am Coll Cardiol. 2006. PMID: 16412857 Free article. Clinical Trial.

9

Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention.

Brook RD, Kansal M, Bard RL, Eagle K, Rubenfire M. Brook RD, et al. Clin Cardiol. 2005 Nov;28(11):534-7. doi: 10.1002/clc.4960281109. Clin Cardiol. 2005. PMID: 16450798 Free PMC article.

10

Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial.

Rajagopalan S, Kariisa M, Dellegrottaglie S, Bard RL, Kehrer C, Matlow S, Daley W, Pitt B, Brook R. Rajagopalan S, et al. Among authors: brook r. J Clin Hypertens (Greenwich). 2006 Nov;8(11):783-90. doi: 10.1111/j.1524-6175.2006.05797.x. J Clin Hypertens (Greenwich). 2006. PMID: 17086018 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

833 results

Search Page